Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $6.6500 (-0.15%) ($6.3300 - $6.7300) on Wed. Aug. 7, 2019. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 3.92% (three month average) | RSI | 29 | Latest Price | $6.6500(-0.15%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX declines -2.3% a day on average for past five trading days. | Weekly Trend | TGTX declines -5.8% a week on average for past two weeks. | Market Behavior | Normal for large cap. Normal for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(65%) ARKG(58%) IBB(58%) ARKK(56%) IWO(56%) | Factors Impacting TGTX price | TGTX will decline at least -1.96% in a week (0% probabilities). VIXM(-39%) VXX(-38%) TLT(-9%) IFRA(-7%) UUP(-6%) | | | | | Relative Volatility | | | | Market Trend Strength | -1.96% (StdDev 3.92%) | Hourly BBV | 0 () | Intraday Trend | 0% | | | |
|
1 - 5 Day Possible Target | $-4.69(-170.53%) | Resistance Level | $7.43 | 5 Day Moving Average | $6.85(-2.92%) | 10 Day Moving Average | $7.1(-6.34%) | 20 Day Moving Average | $7.43(-10.5%) | To recent high | -26% | To recent low | 6.1% | Market Cap | $842m | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |